
HUMIRA Injection 40 mg/0.4 mL
1 Unit
1 Unit
Minimum order quantity: 1 Unit
Open to price negotiation
Supplier Country: Netherlands
Export market: Colombia, Mexico, Costa Rica
Product Specifications
1.1
Netherlands
НИДЕРЛАНДЫZWOLLEZUIDERZEELAAN 53
Export Markets
Based on the information provided by the supplier.
Colombia
Mexico
Costa Rica
Colombia
34%
Mexico
33%
Costa Rica
33%
Verification information
Verification information
Verify business documents
Verify work email
Verify phone number
Verify account email
External Validation
Company Address
Supplier confirmed with Freshdi
Reviews of this Product
No reviews yet
Be the first to share your experience - your feedback helps other buyers trade with confidence.
Product descriptions from the supplier
HUMIRA is a prefilled syringe containing 40 mg of adalimumab in 0.4 mL. This biologic medication is indicated for the treatment of various autoimmune conditions. The prefilled syringe format ensures ease of administration for patients. This product comes with detailed instructions for use. It is typically stored in a refrigerator to maintain its efficacy. HUMIRA is recognized for its effectiveness in managing chronic conditions, making it a vital treatment option for patients.
You are viewing details for HUMIRA Injection 40 mg/0.4 mL. The information provided here is either posted directly by the supplier, who is responsible for its accuracy, or collected by Freshdi AI from publicly available sources. Freshdi strives to make product information as useful and reliable as possible, but we do not guarantee complete accuracy. If you notice any incorrect or misleading details, please use the Report Product option so our team can review and address it quickly.
Contact this Supplier
Medical Injections market insight
Across Medical & HealthCare, the wider group Medical Injections belongs to, Freshdi lists 9 active supply listings from 9 suppliers in 6 countries, as of 21 November 2026. Medical Injections belongs to Medical & HealthCare, whose suppliers on Freshdi come from 6 countries, led by India at 22.2%, as of 21 November 2026. In the 30 days to 21 November 2026, buyer inquiries on Freshdi across Medical & HealthCare, the group Medical Injections belongs to, rose 100% against the 30 days before, with 103.41% volatility in monthly inquiry and quotation activity over 338 days.